TCRX
Price
$8.98
Change
+$0.08 (+0.90%)
Updated
May 17, 6:59 PM EST
81 days until earnings call
YMAB
Price
$11.60
Change
-$0.25 (-2.11%)
Updated
May 17, 6:59 PM EST
81 days until earnings call
Ad is loading...

TCRX vs YMAB

Header iconTCRX vs YMAB Comparison
Open Charts TCRX vs YMABBanner chart's image
TScan Therapeutics
Price$8.98
Change+$0.08 (+0.90%)
Volume$111.74K
CapitalizationN/A
Y-mAbs Therapeutics
Price$11.60
Change-$0.25 (-2.11%)
Volume$232.5K
CapitalizationN/A
View a ticker or compare two or three
TCRX vs YMAB Comparison Chart

Loading...

TCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
YMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
TCRX vs. YMAB commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TCRX is a Hold and YMAB is a Hold.

COMPARISON
Comparison
May 19, 2024
Stock price -- (TCRX: $8.98 vs. YMAB: $11.60)
Brand notoriety: TCRX and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TCRX: 81% vs. YMAB: 102%
Market capitalization -- TCRX: $474.71M vs. YMAB: $509.04M
TCRX [@Biotechnology] is valued at $474.71M. YMAB’s [@Biotechnology] market capitalization is $509.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $586.12B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TCRX’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • TCRX’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, TCRX is a better buy in the long-term than YMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TCRX’s TA Score shows that 6 TA indicator(s) are bullish while YMAB’s TA Score has 4 bullish TA indicator(s).

  • TCRX’s TA Score: 6 bullish, 4 bearish.
  • YMAB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, TCRX is a better buy in the short-term than YMAB.

Price Growth

TCRX (@Biotechnology) experienced а +16.17% price change this week, while YMAB (@Biotechnology) price change was -5.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

TCRX is expected to report earnings on Aug 08, 2024.

YMAB is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for TCRX with price predictions.
OPEN
A.I.dvisor published
a Summary for YMAB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
YMAB($509M) has a higher market cap than TCRX($475M). YMAB YTD gains are higher at: 70.088 vs. TCRX (54.031).
TCRXYMABTCRX / YMAB
Capitalization475M509M93%
EBITDAN/AN/A-
Gain YTD54.03170.08877%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
TCRXYMAB
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 5 days ago
83%
View a ticker or compare two or three
Ad is loading...
TCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
YMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAZCX10.340.02
+0.19%
Russell Inv Multi-Asset Growth Strat C
AEYRX30.140.04
+0.13%
American Century Equity Growth R
IMANX15.270.01
+0.07%
Iman K
DIVGX15.740.01
+0.06%
Guardian Capital Dividend Growth Instl
FSPHX28.85-0.05
-0.17%
Fidelity Select Health Care

TCRX and

Correlation & Price change

A.I.dvisor tells us that TCRX and VSTM have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TCRX and VSTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+0.90%
VSTM - TCRX
32%
Poorly correlated
-5.19%
BCAB - TCRX
26%
Poorly correlated
-8.71%
INBX - TCRX
26%
Poorly correlated
+0.61%
ACHV - TCRX
26%
Poorly correlated
-1.38%
HALO - TCRX
25%
Poorly correlated
-1.50%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ZYME. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-2.11%
ZYME - YMAB
37%
Loosely correlated
-2.77%
SRRK - YMAB
34%
Loosely correlated
-12.78%
SWTX - YMAB
34%
Loosely correlated
+0.16%
XNCR - YMAB
32%
Poorly correlated
+2.54%
MCRB - YMAB
32%
Poorly correlated
-0.49%
More